

## Published Articles - Infectious Diseases

Economic issues in the prevention of vertical transmission of HIV, Ades AE;Ratcliffe J;Gibb DM;Sculpher MJ;, 2000, *Pharmacoeconomics*, 18

Cost effectiveness analysis of antenatal HIV screening in United Kingdom, Ades AE;Sculpher MJ;Gibb DM;Gupta R;Ratcliffe J;, 1999, *British Medical Journal*, 319

HIV patient insight on adhering to medication: a qualitative analysis, Beusterien KM;Davis EA;Flood R;Howard K;Jordan J;, 2008, *AIDS Care*, 20

Understanding patient preferences for HIV medications using adaptive conjoint analysis: feasibility assessment, Beusterien KM;Dziekan K;Flood E;Harding G;Jordan JC;, 2005, *Value Health*, 8

Patient preferences among third agent HIV medications: a US and German perspective, Beusterien KM;Dziekan K;Schrader S;Flood E;Flood R;Shearer A;Davis EA;, 2007, *AIDS Care*, 19

Indoor air mercury concentrations following application of interior latex paint, Beusterien KM;Etzel RA;Agocs MM;Egeland GM;Socie EM;Rouse MA;Mortensen BK;, 1991, *Arch Environ Contam Toxicol*, 21

Interventional cardiovascular procedures among HIV-infected individuals on antiretroviral therapy 1995-2000, Braitstein P;Yip B;Heath KV;Levy AR;Montaner JS;Humphries K;Kiely FM;O'Shaughnessy MV;Hogg RS;, 2003, *AIDS*, 17

Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven?, Briggs AH;Levy AR;, 2006, *Pharmacoeconomics*, 24

Cost implications of alternative treatments for AIDS patients with cryptococcal meningitis. Comparison of fluconazole and amphotericin B-based therapies, Buxton MJ;Dubois DJ;Turner RR;Sculpher MJ;Robinson PA;Searcy C;, 1991, *J Infect Dis*, 23

A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials, Clayson DJ;Wild DJ;Quarterman P;Duprat-Lomon I;Kubin M;Coons SJ;, 2006, *Pharmacoeconomics*, 24

A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery, Cranny G;Elliott R;Weatherly H;Chambers D;Hawkins N;Myers L;Sculpher M;Eastwood A;, 2008, *Health Technol Assess*, 12

Predicting hospitalization among HIV-infected antiretroviral naive patients starting HAART: determining clinical markers and exploring social pathways, Fielden SJ;Rusch ML;Levy AR;Yip B;Wood E;Harrigan RP;Goldstone I;Guillemi S;Montaner JS;Hogg RS;, 2008, *AIDS Care*, 20

Nonadherence increases the risk of hospitalization among HIV-infected antiretroviral naive patients started on HAART, Fielden SJ;Rusch ML;Yip B;Wood E;Shannon K;Levy AR;Montaner JS;Hogg RS;, 2008, *J Int Assoc Physicians AIDS Care (Chic Ill)*, 7

Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection, Gagnon YM;Levy AR;Iloeje UH;Briggs AH;, 2004, *J Clin Gastroenterol*, 38

Costs and benefits to the mother of antenatal HIV testing: estimates from simulation modelling, Gibb DM;Ades AE;Gupta R;Sculpher MJ;, 1999, AIDS, 13

Threats to validity imposed by privacy legislation - What are the potential effects of non-response bias on estimates of association in epidemiological studies?, Harris M.A;Levy AR;Teschke K;, 2008, Canadian Journal of Public Health, 99

Use of instrumental variables in the analysis of generalized linear models in the presence of unmeasured confounding with applications to epidemiological research, Johnston KM;Gustafson P;Levy AR;Grootendorst P;, 2008, Stat Med, 27

Interactive health communication applications for chronic disease: patient and carer perspectives, Kerr C;Murray E;Stevenson F;Gore C;Nazareth I;, 2005, J Telemed Telecare, 11 Suppl 1

The direct costs of HIV/AIDS care, Levy AR;James D;Johnston KM;Hogg RS;Harrigan PR;Harrigan BP;Sobolev B;Montaner JS;, 2006, Lancet Infect Dis, 6

The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons, Levy AR;Kowdley KV;Iloeje U;Tafesse E;Mukherjee J;Gish R;Bzowej N;Briggs AH;, 2008, Value Health, 11

Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS, Levy AR;McCandless L;Harrigan PR;Hogg RS;Bondy G;Iloeje UH;Mukherjee J;Montaner JS;, 2005, Lipids Health Dis, 4

The effect of physicians' training on prescribing beta-blockers for secondary prevention of myocardial infarction in the elderly, Levy AR;Tamblyn RM;McLeod PJ;Fitchett D;Abrahamowicz M;, 2002, Ann Epidemiol, 12

Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic, Lima VD;Johnston K;Hogg RS;Levy AR;Harrigan PR;Anema A;Montaner JS;, 2008, J Infect Dis, 198

Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects, Lloyd A; Patel N;Scott DA;Runge C;Claes C;Rose M;, 2008, Eur J Health Econ, 9

In an observational study, measured confounders were used to model uncertainty from unmeasured confounding., McCandless L.C.;Gustafson P;Levy AR;, 2008, J Clin Epidemiol, 61

A sensitivity analysis using information about measured confounders yielded improved uncertainty assessments for unmeasured confounding, McCandless LC;Gustafson P;Levy AR;, 2008, J Clin Epidemiol, 61

Re-evaluating to the effectiveness of highly active antiretroviral therapy - the case for expanding treatment access to curb the growth of the epidemic., Montaner JS;Hogg R;Wood E;Kerr T;Tyndall M;Levy AR;Harrigan PR;, 2006, Lancet, 368

The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic, Montaner JS;Hogg R;Wood E;Kerr T;Tyndall M;Levy AR;Harrigan PR;, 2006, Lancet, 368

Alternative strategies for prevention of mother-to-child transmission of HIV-1 infection and their cost-effectiveness., Ratcliffe J;Ades AE;Gibb D;Sculpher MJ;, 1998, AIDS, 12

Prevention of mother-to-child transmission of HIV-1 infection: alternative strategies and their cost-effectiveness, Ratcliffe J;Ades AE;Gibb D;Sculpher MJ;Briggs AH;, 1998, AIDS, 12

Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy, Recsky MA;Brumme ZL;Chan KJ;Wynhoven B;Yip B;Dong WW;Heath KV;Montaner JS;Levy AR;Hogg RS;Harrigan PR;, 2004, J Infect Dis, 190

The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia, Ryan M;Griffin S;Chitah B;Walker AS;Mulenga V;Kalolo D;Hawkins N;Merry C;Barry MG;Chintu C;Sculpher MJ;Gibb DM;, 2008, AIDS, 22

Plasma concentrations of reputed tumor-associated soluble CD44 isoforms (v5 and v6) in smokers are dose related and decline on smoking cessation, Scott DA;Stapleton JA;Palmer RM;Wilson RF;Sutherland G;Coward PY;Gustavsson G;Odell EW;Poston RN;, 2000, Cancer Epidemiol Biomarkers Prev, 9

Modelling the costs of paediatric HIV infection and AIDS: comparison of infected children born to screened and unscreened mothers, Sculpher MJ;Gibb D;Ades AE;Ratcliffe J;Duong T;, 1998, AIDS, 12